About Xxxxx. Xxxxx is the world’s fourth-largest family-owned automotive supplier. The company develops and produces mechatronic systems for vehicle doors and seats as well as electric motors, drives and electronics for steering, brakes, transmissions and engine cooling.
About Xxxxx. 2.1 Xxxxx is an associate of Xxxxx & XxXxxxxx Companies, Inc. In these STACs, the Xxxxx Group means Xxxxx & XxXxxxxx Companies, Inc., its subsidiaries and associated companies. To the extent legally permissible, Xxxxx may use offices in the Xxxxx Group or the services of other intermediaries external to the Xxxxx Group, when in Xxxxx’x professional judgement those services are necessary or appropriate.
About Xxxxx. Xxxxx Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Xxxxx’x pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA-approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. (TAVLESSE), the United Kingdom (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. Fostamatinib is currently being studied in a Phase 3 clinical trial (NCT03764618) for the treatment of warm autoimmune hemolytic anemia (wAIHA)5; a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with COVID-195 and an XXX/XXXXX-xxxxxxxxx Xxxxx 0 clinical trial (ACTIV-4 Host Tissue Trial, NCT04924660) for the treatment of COVID-19 in hospitalized patients. Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program in clinical development with partner Xxx Xxxxx and Company. In addition, Xxxxx has product candidates in development with partners XxxXxxXxx XXX and Daiichi Sankyo. For further information, visit xxx.xxxxx.xxx or follow us on Twitter or LinkedIn. Please see xxx.XXXXXXXXX.xxx for full Prescribing Information.
About Xxxxx. ❖ The mission was launched in 2015 by PM Modi for urban renewal by March 2020. ❖ The programme was preceded by Xxxxxxxxxx Xxxxx National Urban Renewal Mission (JNNURM). ❖ The Mission will focus on the Thrust Areas like Water Supply, Sewerage management, etc. ❖ The Mission covers 500 cities that includes all cities and towns with a population of over one lakh with notified Municipalities.
About Xxxxx. Xxxxx is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us
About Xxxxx. XXXXX modernizes and streamlines the manufacturing industry. We create shorter lead time with more environmentally friendly processes and increase profitability for clients by bringing together different manufacturing technologies locally. Founded in 2008, HANZA today has an annual revenue of more than one million SEK and operates in Sweden, Finland, Estonia, Poland, Czech Republic and China. Among HANZA’s clients are leading companies like ABB, Xxxxxx Xxxxx, Atlas Copco and Kone. For more information visit xxx.xxxxx.xxx.
About Xxxxx. Xxxxx Document Automation Asia Pte Ltd., with principal place of business at 00 Xxxxxx Xxxx, #00-00, Xxxxxxxx Xxxxxx, Xxxxxxxxx 000000. Tel: +00 0000 000
About Xxxxx. Xxxxx is a pioneer in telecommunications and digital services. We serve approximately 2.8 million consumer, corporate and public administration organisation customers, and have over 6.3 million subscriptions in our extensive network. Cooperation with Vodafone and Tele2, among others, enables globally competitive services. Our core markets are Finland and Estonia, and we also provide digital services for international markets. Elisa’s shares are listed on the Nasdaq Helsinki. In 2019, our revenue was EUR 1.84 billion, and we employed 4,900 people. As a responsible Finnish market leader, our operations are guided by continuous improvement. We will be a carbon neutral company from 2020 onwards. Further information on xxx.xxxxx.xxx, Facebook (@elisasuomi) and Twitter (@ElisaOyj).
About Xxxxx. Xxxxx is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell- based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
About Xxxxx. Xxxxx is a leading global supplier of catalysts and other products to petroleum refiners; catalysts for the manufacture of plastics; silica-based engineered and specialty materials for a wide range of industrial applications; sealants and coatings for food and beverage packaging, and specialty chemicals, additives and building materials for commercial and residential construction. Founded in 1854, Grace has operations in over 40 countries. For more information, visit Grace’s web site at xxx.xxxxx.xxx.
